<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33199452</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1488-2329</ISSN><JournalIssue CitedMedium="Internet"><Volume>192</Volume><Issue>46</Issue><PubDate><Year>2020</Year><Month>Nov</Month><Day>16</Day></PubDate></JournalIssue><Title>CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne</Title><ISOAbbreviation>CMAJ</ISOAbbreviation></Journal><ArticleTitle>Canadian best practice recommendations for the management of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>E1453</StartPage><EndPage>E1468</EndPage><MedlinePgn>E1453-E1468</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1503/cmaj.191721</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shoesmith</LastName><ForeName>Christen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre (Shoesmith), London, Ont.; Sunnybrook Health Sciences Centre (Abrahao, Izenberg, Tandon, Zinman), Toronto, Ont.; Dalhousie University (Benstead, Leddin), Halifax, NS; McMaster University (Chum), Hamilton, Ont.; CHU de Qu&#xe9;bec-Universit&#xe9; Laval (Dupre), Qu&#xe9;bec, Que.; University of Alberta (Johnston, Kalra), Edmonton, Alta.; Stan Cassidy Centre for Rehabilitation (O'Connell), Fredericton, NB; University of Saskatchewan (Schellenberg), Saskatoon, Sask. Christen.Shoesmith@lhsc.on.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrahao</LastName><ForeName>Agessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre (Shoesmith), London, Ont.; Sunnybrook Health Sciences Centre (Abrahao, Izenberg, Tandon, Zinman), Toronto, Ont.; Dalhousie University (Benstead, Leddin), Halifax, NS; McMaster University (Chum), Hamilton, Ont.; CHU de Qu&#xe9;bec-Universit&#xe9; Laval (Dupre), Qu&#xe9;bec, Que.; University of Alberta (Johnston, Kalra), Edmonton, Alta.; Stan Cassidy Centre for Rehabilitation (O'Connell), Fredericton, NB; University of Saskatchewan (Schellenberg), Saskatoon, Sask.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benstead</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre (Shoesmith), London, Ont.; Sunnybrook Health Sciences Centre (Abrahao, Izenberg, Tandon, Zinman), Toronto, Ont.; Dalhousie University (Benstead, Leddin), Halifax, NS; McMaster University (Chum), Hamilton, Ont.; CHU de Qu&#xe9;bec-Universit&#xe9; Laval (Dupre), Qu&#xe9;bec, Que.; University of Alberta (Johnston, Kalra), Edmonton, Alta.; Stan Cassidy Centre for Rehabilitation (O'Connell), Fredericton, NB; University of Saskatchewan (Schellenberg), Saskatoon, Sask.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chum</LastName><ForeName>Marvin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre (Shoesmith), London, Ont.; Sunnybrook Health Sciences Centre (Abrahao, Izenberg, Tandon, Zinman), Toronto, Ont.; Dalhousie University (Benstead, Leddin), Halifax, NS; McMaster University (Chum), Hamilton, Ont.; CHU de Qu&#xe9;bec-Universit&#xe9; Laval (Dupre), Qu&#xe9;bec, Que.; University of Alberta (Johnston, Kalra), Edmonton, Alta.; Stan Cassidy Centre for Rehabilitation (O'Connell), Fredericton, NB; University of Saskatchewan (Schellenberg), Saskatoon, Sask.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dupre</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre (Shoesmith), London, Ont.; Sunnybrook Health Sciences Centre (Abrahao, Izenberg, Tandon, Zinman), Toronto, Ont.; Dalhousie University (Benstead, Leddin), Halifax, NS; McMaster University (Chum), Hamilton, Ont.; CHU de Qu&#xe9;bec-Universit&#xe9; Laval (Dupre), Qu&#xe9;bec, Que.; University of Alberta (Johnston, Kalra), Edmonton, Alta.; Stan Cassidy Centre for Rehabilitation (O'Connell), Fredericton, NB; University of Saskatchewan (Schellenberg), Saskatoon, Sask.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izenberg</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre (Shoesmith), London, Ont.; Sunnybrook Health Sciences Centre (Abrahao, Izenberg, Tandon, Zinman), Toronto, Ont.; Dalhousie University (Benstead, Leddin), Halifax, NS; McMaster University (Chum), Hamilton, Ont.; CHU de Qu&#xe9;bec-Universit&#xe9; Laval (Dupre), Qu&#xe9;bec, Que.; University of Alberta (Johnston, Kalra), Edmonton, Alta.; Stan Cassidy Centre for Rehabilitation (O'Connell), Fredericton, NB; University of Saskatchewan (Schellenberg), Saskatoon, Sask.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>Wendy</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre (Shoesmith), London, Ont.; Sunnybrook Health Sciences Centre (Abrahao, Izenberg, Tandon, Zinman), Toronto, Ont.; Dalhousie University (Benstead, Leddin), Halifax, NS; McMaster University (Chum), Hamilton, Ont.; CHU de Qu&#xe9;bec-Universit&#xe9; Laval (Dupre), Qu&#xe9;bec, Que.; University of Alberta (Johnston, Kalra), Edmonton, Alta.; Stan Cassidy Centre for Rehabilitation (O'Connell), Fredericton, NB; University of Saskatchewan (Schellenberg), Saskatoon, Sask.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalra</LastName><ForeName>Sanjay</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre (Shoesmith), London, Ont.; Sunnybrook Health Sciences Centre (Abrahao, Izenberg, Tandon, Zinman), Toronto, Ont.; Dalhousie University (Benstead, Leddin), Halifax, NS; McMaster University (Chum), Hamilton, Ont.; CHU de Qu&#xe9;bec-Universit&#xe9; Laval (Dupre), Qu&#xe9;bec, Que.; University of Alberta (Johnston, Kalra), Edmonton, Alta.; Stan Cassidy Centre for Rehabilitation (O'Connell), Fredericton, NB; University of Saskatchewan (Schellenberg), Saskatoon, Sask.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leddin</LastName><ForeName>Desmond</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre (Shoesmith), London, Ont.; Sunnybrook Health Sciences Centre (Abrahao, Izenberg, Tandon, Zinman), Toronto, Ont.; Dalhousie University (Benstead, Leddin), Halifax, NS; McMaster University (Chum), Hamilton, Ont.; CHU de Qu&#xe9;bec-Universit&#xe9; Laval (Dupre), Qu&#xe9;bec, Que.; University of Alberta (Johnston, Kalra), Edmonton, Alta.; Stan Cassidy Centre for Rehabilitation (O'Connell), Fredericton, NB; University of Saskatchewan (Schellenberg), Saskatoon, Sask.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Connell</LastName><ForeName>Colleen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre (Shoesmith), London, Ont.; Sunnybrook Health Sciences Centre (Abrahao, Izenberg, Tandon, Zinman), Toronto, Ont.; Dalhousie University (Benstead, Leddin), Halifax, NS; McMaster University (Chum), Hamilton, Ont.; CHU de Qu&#xe9;bec-Universit&#xe9; Laval (Dupre), Qu&#xe9;bec, Que.; University of Alberta (Johnston, Kalra), Edmonton, Alta.; Stan Cassidy Centre for Rehabilitation (O'Connell), Fredericton, NB; University of Saskatchewan (Schellenberg), Saskatoon, Sask.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schellenberg</LastName><ForeName>Kerri</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre (Shoesmith), London, Ont.; Sunnybrook Health Sciences Centre (Abrahao, Izenberg, Tandon, Zinman), Toronto, Ont.; Dalhousie University (Benstead, Leddin), Halifax, NS; McMaster University (Chum), Hamilton, Ont.; CHU de Qu&#xe9;bec-Universit&#xe9; Laval (Dupre), Qu&#xe9;bec, Que.; University of Alberta (Johnston, Kalra), Edmonton, Alta.; Stan Cassidy Centre for Rehabilitation (O'Connell), Fredericton, NB; University of Saskatchewan (Schellenberg), Saskatoon, Sask.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tandon</LastName><ForeName>Anu</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre (Shoesmith), London, Ont.; Sunnybrook Health Sciences Centre (Abrahao, Izenberg, Tandon, Zinman), Toronto, Ont.; Dalhousie University (Benstead, Leddin), Halifax, NS; McMaster University (Chum), Hamilton, Ont.; CHU de Qu&#xe9;bec-Universit&#xe9; Laval (Dupre), Qu&#xe9;bec, Que.; University of Alberta (Johnston, Kalra), Edmonton, Alta.; Stan Cassidy Centre for Rehabilitation (O'Connell), Fredericton, NB; University of Saskatchewan (Schellenberg), Saskatoon, Sask.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zinman</LastName><ForeName>Lorne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre (Shoesmith), London, Ont.; Sunnybrook Health Sciences Centre (Abrahao, Izenberg, Tandon, Zinman), Toronto, Ont.; Dalhousie University (Benstead, Leddin), Halifax, NS; McMaster University (Chum), Hamilton, Ont.; CHU de Qu&#xe9;bec-Universit&#xe9; Laval (Dupre), Qu&#xe9;bec, Que.; University of Alberta (Johnston, Kalra), Edmonton, Alta.; Stan Cassidy Centre for Rehabilitation (O'Connell), Fredericton, NB; University of Saskatchewan (Schellenberg), Saskatoon, Sask.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017065">Practice Guideline</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>CMAJ</MedlineTA><NlmUniqueID>9711805</NlmUniqueID><ISSNLinking>0820-3946</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010348" MajorTopicYN="Y">Patient Care Team</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="Y">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012955" MajorTopicYN="N">Societies, Medical</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: Christen Shoesmith, Aaron Izenberg, Wendy Johnston, Colleen O&#x2019;Connell, Kerri Schellenberg and Lorne Zinman were members of a scientific advisory committee for Radicava (edaravone; Mitsubishi Tanabe Pharma Canada). Christen Shoesmith reports being a site principal investigator for several multicentre amyotrophic lateral sclerosis (ALS) clinical trials. In the last 36 months, Dr. Shoesmith has participated in clinical trials sponsored by Biogen, Cytokinetics, ALS Pharma and Orphazyme. Marvin Chum reports receiving a grant from Bernice Ramsay ALS Clinical Research Fellowship, outside the submitted work. Aaron Izenberg reports receiving personal fees from Biogen, Roche, Alnylam, Genzyme, Takeda and Mitsubishi Tanabe Pharma, outside the submitted work. No other competing interests were declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33199452</ArticleId><ArticleId IdType="pmc">PMC7683000</ArticleId><ArticleId IdType="doi">10.1503/cmaj.191721</ArticleId><ArticleId IdType="pii">192/46/E1453</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med 2017;377:162&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet 2017;390:2084&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. Amyotrophic lateral sclerosis &#x2014; frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:153&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoesmith C. A recipe for ALS. Can J Neurol Sci 2008;35:125&#x2013;126.</Citation><ArticleIdList><ArticleId IdType="pubmed">18574922</ArticleId></ArticleIdList></Reference><Reference><Citation>Health Canada approves new drug to treat patients with amyotrophic lateral sclerosis (ALS) [press release]. Ottawa: Health Canada; 2018. October 4.</Citation></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1218&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764727</ArticleId><ArticleId IdType="pubmed">19822872</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2009;73:1227&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2764728</ArticleId><ArticleId IdType="pubmed">19822873</ArticleId></ArticleIdList></Reference><Reference><Citation>The EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis Andersen PM, Abrahams S, Borasio GD, et al. EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) &#x2013; revised report of an EFNS task force. Eur J Neurol 2012;19:360&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference><Reference><Citation>Motor neurone disease: assessment and management (NG42). London (UK): National Institute for Healthcare and Excellence (NICE); 2016.</Citation></Reference><Reference><Citation>Peters M, Fitzpatrick R, Doll H, et al. Patients&#x2019; experiences of health and social care in long-term neurological conditions in England: a cross-sectional survey. J Health Serv Res Policy 2013;18:28&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">23393039</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdulla S, Vielhaber S, Machts J, et al. Information needs and information-seeking preferences of ALS patients and their carers. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:505&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">25007829</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang K, Umapathi T, Tong J, et al. Healthcare needs of patients with amyotrophic lateral sclerosis (ALS) in Singapore: a patient-centred qualitative study from multiple perspectives. J Palliat Care 2015;31:150&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26514020</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Montuschi A, Cammarosano S, et al. ALS patients and caregivers communication preferences and information seeking behaviour. Eur J Neurol 2008;15:55&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">18005051</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012; (3):CD001447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J, Byrne S, Heverin M, et al. Survival analysis of irish amyotrophic lateral sclerosis patients diagnosed from 1995&#x2013;2010. PLoS One 2013;8:e74733.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786977</ArticleId><ArticleId IdType="pubmed">24098664</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevic Z, Kostic-Dedic S, Peric S, et al. Prognostic factors and survival of ALS patients from Belgrade, Serbia. Amyotroph Lateral Scler Frontotemporal Degener 2016;17:508&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">27315438</ArticleId></ArticleIdList></Reference><Reference><Citation>Georgoulopoulou E, Fini N, Vinceti M, et al. The impact of clinical factors, riluzole and therapeutic interventions on ALS survival: a population-based study in Modena, Italy. Amyotroph Lateral Scler Frontotemporal Degener 2013; 14:338&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">23373475</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q, Chen X, Zheng Z, et al. The predictors of survival in Chinese amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:237&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">25581512</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Liu X, Tang L, et al. Long-term use of riluzole could improve the prognosis of sporadic amyotrophic lateral sclerosis patients: a real-world cohort study in China. Front Aging Neurosci 2016;8:246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5075535</ArticleId><ArticleId IdType="pubmed">27822184</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandrioli J, Malerba SA, Beghi E, et al. Riluzole and other prognostic factors in ALS: a population-based registry study in Italy. J Neurol 2018;265:817&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">29404735</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xed;vori M, Rodriguez GE, Pascansky D, et al. Outcome of sporadic amyotrophic lateral sclerosis treated with non-invasive ventilation and riluzole. Medicina (B Aires) 2007;67:326&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">17891927</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CT, Chiu YW, Wang KC, et al. Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-term survival: a population-based study of 1149 cases in Taiwan. J Epidemiol 2013;23:35&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3700231</ArticleId><ArticleId IdType="pubmed">23117224</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe H, Atsuta N, Nakamura R, et al. Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:230&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25548957</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A, Moglia C, Lunetta C, et al. Factors predicting survival in ALS: a multi-center Italian study. J Neurol 2017;264:54&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">27778156</ArticleId></ArticleIdList></Reference><Reference><Citation>Keren N, Scott KM, Tsuda M, et al. Evidence of an environmental effect on survival in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:528&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">24862874</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Meurgey JH, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol 2018;17:416&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5899963</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Wei QQ, Chen Y, et al. Clinical staging of amyotrophic lateral sclerosis in Chinese patients. Front Neurol 2018;9:442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6018204</ArticleId><ArticleId IdType="pubmed">29971035</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoccolella S, Beghi E, Palagano G, et al. Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy. Eur J Neurol 2007;14:262&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17355545</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group, Edaravone ALSSG. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J, Byrne S, Heverin M, et al. A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland. J Neurol Neurosurg Psychiatry 2015;86:496&#x2013;501.</Citation><ArticleIdList><ArticleId IdType="pubmed">25550416</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Alexander M, Corr B, et al. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population-based study, 1996&#x2013;2000. J Neurol Neurosurg Psychiatry 2003;74:1258&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1738639</ArticleId><ArticleId IdType="pubmed">12933930</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Berg JP, Kalmijn S, Lindeman E, et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology 2005;65:1264&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16247055</ArticleId></ArticleIdList></Reference><Reference><Citation>Geronimo A, Wright C, Morris A, et al. Incorporation of telehealth into a multidisciplinary ALS Clinic: feasibility and acceptability. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:555&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">28678542</ArticleId></ArticleIdList></Reference><Reference><Citation>Rimmer KP, Kaminska M, Nonoyama M, et al. Home mechanical ventilation for patients with amyotrophic lateral sclerosis: a Canadian Thoracic Society clinical practice guideline. Can J Respir Cri Care Sleep Med 2019;3:9&#x2013;27.</Citation></Reference><Reference><Citation>Gonzalez Calzada N, Prats Soro E, Mateu Gomez L, et al. Factors predicting survival in amyotrophic lateral sclerosis patients on non-invasive ventilation. Amyotroph Lateral Scler Frontotemporal Degener 2016;17:337&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">27046344</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva LB, Mourao LF, Silva AA, et al. Effect of nutritional supplementation with milk whey proteins in amyotrophic lateral sclerosis patients. Arq Neuropsiquiatr 2010;68:263&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">20464297</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, Cypionka J, Ludolph AC. High-caloric food supplements in the treatment of amyotrophic lateral sclerosis: a prospective interventional study. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:533&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">23944684</ArticleId></ArticleIdList></Reference><Reference><Citation>Wills AM, Hubbard J, Macklin EA, et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 2014;383:2065&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4176708</ArticleId><ArticleId IdType="pubmed">24582471</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman M, Dehaan M, Pinto H, et al. Venous thromboembolism in amyotrophic lateral sclerosis: a prospective study. Neurology 2014;82:1674&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4032202</ArticleId><ArticleId IdType="pubmed">24727309</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi MM, Cudkowicz ME, Zhang H, et al. Increased incidence of deep venous thrombosis in ALS. Neurology 2007;68:76&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17200499</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson CE, Gronseth G, Rosenfeld J, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 2009; 39:137&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">19145653</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Thisted RA, Appel SH, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004; 63:1364&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">15505150</ArticleId></ArticleIdList></Reference><Reference><Citation>Caron J, Light J. My world has expanded even though i&#x2019;m stuck at home&#x201d;: experiences of individuals with amyotrophic lateral sclerosis who use augmentative and alternative communication and social media. Am J Speech Lang Pathol 2015;24:680&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">26254447</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang C-S, Weng H-H, Wang L-F, et al. An eye-tracking assistive device improves the quality of life for ALS patients and reduces the caregivers&#x2019; burden. J Mot Behav 2014;46:233&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">24731126</ArticleId></ArticleIdList></Reference><Reference><Citation>Clawson LL, Cudkowicz M, Krivickas L, et al. A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2018;19:250&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29191052</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Lizio A, Sansone VA, et al. Strictly monitored exercise programs reduce motor deterioration in ALS: preliminary results of a randomized controlled trial. J Neurol 2016;263:52&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">26477027</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin M, Phukan J, Bede P, et al. Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia. Neurology 2011; 76:1263&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">21464431</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke T, Hardiman O, Pinto-Grau M, et al. Longitudinal predictors of caregiver burden in amyotrophic lateral sclerosis: a population-based cohort of patient-caregiver dyads. J Neurol 2018;265:793&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pubmed">29396678</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerum SV, Solbraekke KN, Frich JC. Family caregivers&#x2019; accounts of caring for a family member with motor neurone disease in Norway: a qualitative study. BMC Palliat Care 2016;15:22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4765180</ArticleId><ArticleId IdType="pubmed">26911713</ArticleId></ArticleIdList></Reference><Reference><Citation>Watermeyer TJ, Brown RG, Sidle KC, et al. Impact of disease, cognitive and behavioural factors on caregiver outcome in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:316&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">26199108</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley G, Timonen V, Hardiman O. &#x201c;I hate being a burden&#x201d;: the patient perspective on carer burden in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2016;17:351&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26857752</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Bromberg M, Johnston W, et al. Promoting excellence in end-of-life care in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6:145&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">16183556</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray RA, Brown J, Street AF. Dying with motor neurone disease, what can we learn from family caregivers? Health Expect 2014;17:466&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5060749</ArticleId><ArticleId IdType="pubmed">22512686</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; D, Nonnenmacher S, Sorg S, et al. Live and let die: existential decision processes in a fatal disease. J Neurol 2014;261:518&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">24413639</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray L, Butow PN, White K, et al. Advance care planning in motor neuron disease: A qualitative study of caregiver perspectives. Palliat Med 2016;30:471&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">26847526</ArticleId></ArticleIdList></Reference><Reference><Citation>Burchardi N, Rauprich O, Hecht M, et al. Discussing living wills. A qualitative study of a German sample of neurologists and ALS patients. J Neurol Sci 2005;237:67&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">16009378</ArticleId></ArticleIdList></Reference><Reference><Citation>Preston H, Fineberg IC, Callagher P, et al. The preferred priorities for care document in motor neurone disease: views of bereaved relatives and carers. Palliat Med 2012;26:132&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21383060</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulmasy DP, Terry PB, Weisman CS, et al. The accuracy of substituted judgments in patients with terminal diagnoses. Ann Intern Med 1998;128:621&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9537935</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xfc;nemann HJ, Wiercioch W, Etxeandia I, et al. Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. CMAJ 2014;186:E123&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3928232</ArticleId><ArticleId IdType="pubmed">24344144</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical practice guideline process manual. St. Paul (MN): AAN (American Academy of Neurology); 2011.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>